🇪🇸 Leer este artículo en español

⚖️ Transparency notice: this article was written with AI assistance and reviewed by the author, a medical oncologist.

What if radiotherapy could be designed to awaken the immune system?

For a decade we have assumed a division of roles: radiotherapy controls locally and immunotherapy works at a distance. The combination of both has almost always relied on the same scheme — conventional or stereotactic (SBRT) radiotherapy + checkpoint inhibitors. But a review published in Biomedicines (July 2026) by two radiation oncologists from the University of Miami raises something more provocative: the immunological potential of radiation does not depend solely on the dose, but on how it is delivered.

What does the article say?

Mihaylov and Spieler review five families of “non-conventional” radiotherapy strategies, each with a distinct radiobiological signature, designed to be combined with immunotherapy: spatially fractionated radiotherapy (GRID/LATTICE), very low-dose radiotherapy (LDRT), targeted radionuclide therapy and theranostics, radiosensitizing nanoparticles, and locoregional immunotherapy (intratumoral or CAR-T).

What it contributes: three ideas backed by data

1. Dose architecture matters as much as dose. Spatially fractionated radiotherapy deliberately abandons uniform dosing: it creates ablative peaks and low-dose valleys within the same tumor. The advantage is twofold: the peaks kill tumor cells and release neoantigens, while the valleys (<5 Gy) preserve perfusion and T lymphocyte trafficking. In a clinical case of bulky metastatic NSCLC that had progressed to palliative radiotherapy, high-dose LATTICE + anti-PD-1 achieved a 78% volume reduction at one month and complete local response at 5 months (PMID 33643893). Note: it is an isolated case (n=1), but illustrates the mechanism.

2. Sometimes, less dose is more immunology. LDRT (0.5–2 Gy per fraction) does not kill cells: it reprograms the cold tumor microenvironment — that of tumors without T-cell infiltration — by recruiting lymphocytes, monocytes, and NK cells in an interferon-dependent manner. In a phase I trial combining LDRT with low-dose cyclophosphamide and dual checkpoint blockade in immunologically cold gastrointestinal, prostate, and ovarian tumors, objective responses were observed in 37% of patients, with Th1 infiltration and NKG2D-dependent cytotoxicity in responders (PMID 34479871).

3. Radiation can become systemic. Targeted radionuclide therapy (177Lu-PSMA-617 in prostate cancer, 177Lu-DOTATATE in neuroendocrine tumors) irradiates all metastases from a single dose. In preclinical models of immunotherapy-resistant tumors, TRT with 90Y-NM600 (2.5–5 Gy) + ICI produced complete responses in 45–66% of mice, compared to 0% with each treatment alone, via STING activation (PMID 34261797).

😬 But with caution

• Most of the evidence is preclinical or early-phase. The most robust randomized trial cited (Act.In.Sarc, phase 2-3, Lancet Oncol 2019, PMID 31296491) demonstrated that the NBTXR3 nanoparticle enhances radiotherapy in soft tissue sarcomas — but as a radiosensitizer, not as a combination with immunotherapy.
• The 37% from the phase I and the 78% from the clinical case are promising figures, not standards: small samples, without randomized comparator.
• The authors themselves acknowledge it: the field’s problem is not a lack of convincing biology, but excess. Each modality fits a distinct tumor phenotype, and there are still no prospective trials with biomarkers to say which one to use for each patient.

💡 Why it matters to the clinician

Radiotherapy is no longer “one size fits all”. In the coming years, decisions about when and how to irradiate a patient on immunotherapy will be richer multidisciplinary decisions: radiation oncology, nuclear medicine, immunology, and medical oncology will have to choose between ablative dose, low dose, radionuclide, or nanoparticle according to the tumor’s immune phenotype. For the medical oncologist, this means that the question is no longer just “do we irradiate?”, but “with what dose architecture?”.

Reflection

Radiation has always been more than an invisible scalpel: it is a modulator of the immune system whose “format” of administration can decide whether the response stays within the irradiated field or spreads throughout the body. The good news is that the tools exist. The pending task is to learn how to pair them with the right tumor. Interestingly, the authors acknowledge in the article itself

— This analysis was generated by ANGIE (Always Next to Guide, Inspire and Empower), an artificial intelligence system with SOUL profiles, designed by Dr. Javier Pumares Pérez.

Connect on LinkedIn · ppj.es